Wang Peng, Zhang Dong, Guo Xue-Guang, Li Xiao-Mei, Du Le-Hui, Sun Bao-Jun, Fang Xiang-Qun, Guo Ying-Hua, Guo Jun, An Li, Qu Ge-Ping, Liu Chang-Ting
Nanlou Medical Oncology Department Radiation Oncology Department Nanlou Respiratory Diseases Department, Chinese People's Liberation Army General Hospital, Beijing, China.
Medicine (Baltimore). 2016 Dec;95(52):e5723. doi: 10.1097/MD.0000000000005723.
Elderly patients with early stage non-small cell lung cancer (NSCLC) who undergo surgical resection are at a high risk of treatment-related complications. Stereotactic body radiation therapy (SBRT) is considered an alternative treatment option with a favorable safety profile. Given that prospective comparative data on SBRT and surgical treatments are limited, we compared the 2 treatments for early stage NSCLC in the elderly.We retrospectively collected information from the database at our geriatric institution on patients with clinical stage IA/B NSCLC who were treated with surgery or SBRT. The patients were matched using a propensity score based on gender, age, T stage, tumor location, pulmonary function (forced expiratory volume in 1 second [FEV1]% and FEV1), Charlson comorbidity score, and World Health Organization performance score. We compared locoregional control rate, recurrence-free survival (RFS), overall survival (OS), and cancer-specific survival (CSS) between the 2 treatment cohorts before and after propensity score matching.A total of 106 patients underwent surgery, and 74 received SBRT. Surgical patients were significantly younger (72.6 ± 7.9 vs 82.6 ± 4.1 years, P = 0.000), with a significantly higher rate of adenocarcinoma (P = 0.000), better Eastern Cooperative Oncology Group performance scores (P = 0.039), and better pulmonary function test results (P = 0.034 for predicted FEV1 and P = 0.032 for FEV1). In an unmatched comparison, there were significant differences in locoregional control (P = 0.0012) and RFS (P < 0.001). The 5-year OS was 69% in patients who underwent surgery and 44.6% in patients who underwent SBRT (P = 0.0007). The 5-year CSS was 73.9% in the surgery group and 57.5% in the SBRT group (P = 0.0029). Thirty-five inoperable or marginally operable surgical patients and 35 patients who underwent SBRT were matched to their outcomes in a blinded manner (1:1 ratio, caliper distance = 0.25). In this matched comparison, the follow-up period of this subgroup ranged from 4.2 to 138.1 months, with a median of 58.7 months. Surgery was associated with significantly better locoregional control (P = 0.0191) and RFS (P = 0.0178), whereas no significant differences were found in OS (5-year OS, 67.8% for surgery vs 47.4% for SBRT, P = 0.07) or CSS (67.8% for surgery vs 58.2% for SBRT, P = 0.1816).This retrospective analysis found superior locoregional control rates and RFS after surgery compared with SBRT, but there were no differences in OS or CSS. SBRT is an alternative treatment option to surgery in elderly NSCLC patients who cannot tolerate surgical resection because of medical comorbidities. Our findings support the need to compare the 2 treatments in randomized controlled trials.
接受手术切除的老年早期非小细胞肺癌(NSCLC)患者发生治疗相关并发症的风险很高。立体定向体部放射治疗(SBRT)被认为是一种安全性良好的替代治疗选择。鉴于SBRT与手术治疗的前瞻性对比数据有限,我们比较了这两种治疗方法在老年早期NSCLC患者中的疗效。我们回顾性收集了我们老年病机构数据库中接受手术或SBRT治疗的临床IA/B期NSCLC患者的信息。根据性别、年龄、T分期、肿瘤位置、肺功能(一秒用力呼气容积[FEV1]%和FEV1)、Charlson合并症评分和世界卫生组织体能状态评分,使用倾向评分对患者进行匹配。我们比较了倾向评分匹配前后两个治疗队列的局部区域控制率、无复发生存期(RFS)、总生存期(OS)和癌症特异性生存期(CSS)。共有106例患者接受了手术,74例接受了SBRT。手术患者明显更年轻(72.6±7.9岁 vs 82.6±4.1岁,P = 0.000),腺癌发生率明显更高(P = 0.000),东部肿瘤协作组体能状态评分更好(P = 0.039),肺功能测试结果更好(预测FEV1的P = 0.034,FEV1的P = 0.032)。在未匹配的比较中,局部区域控制(P = 0.0012)和RFS(P < 0.001)存在显著差异。接受手术的患者5年总生存率为69%,接受SBRT的患者为44.6%(P = 0.0007)。手术组5年癌症特异性生存率为73.9%,SBRT组为57.5%(P = 0.0029)。35例无法手术或勉强可手术的手术患者和35例接受SBRT的患者以盲法匹配其结局(1:1比例,卡尺距离 = 0.25)。在这种匹配比较中,该亚组的随访期为4.2至138.1个月,中位数为58.7个月。手术与明显更好的局部区域控制(P = 0.0191)和RFS(P = 0.0178)相关,而在OS(5年OS,手术组为67.8%,SBRT组为47.4%,P = 0.07)或CSS(手术组为67.8%,SBRT组为58.2%,P = 0.1816)方面未发现显著差异。这项回顾性分析发现,与SBRT相比,手术后的局部区域控制率和RFS更高,但在OS或CSS方面没有差异。对于因合并症而无法耐受手术切除的老年NSCLC患者,SBRT是手术的替代治疗选择。我们的研究结果支持在随机对照试验中比较这两种治疗方法的必要性。